Vortioxetine
Cognitive Impairment With Primary Psychotic Disorder
Fundación Pública Andaluza para la gestión de la Investigación en SevillaSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
36 Active assets in the Cognitive Impairment With Primary Psychotic Disorder cohort.
View all 50 →
Same molecule, other indications
Vortioxetine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →